Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

Intellia Therapeutics

Status: Enrolling

Conditions: Wild-Type Transthyretin Cardiac Amyloidosis; Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy; Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

Study type: Observational

Funder types: Industry

Identifiers

NCT05697861

2022-003405-30 (EudraCT Number)

ITL-2001-CL-999

Details and patient eligibility

About

This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

Enrollment: 72 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received.
2. A subject has provided informed consent for the LTFU study.

Exclusion criteria

None